title: The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
abstract: Prostate cancer (PC) is the most common cancer in men in the United States. Although outcomes are excellent for early-stage disease, survival for men with metastatic PC is limited. While older studies did not supported the use of chemotherapy in PC, the efficacy of taxane chemotherapy plus prednisone is now well established in men with metastatic castration resistant PC (CRPC). The results of CHAARTED trial have further expanded the use of chemotherapy to patients with metastatic hormone-sensitive disease. The clinical efficacy of taxanes over other chemotherapeutics may be a result of its ability to inhibit microtubule-dependent trafficking of proteins such as the androgen-receptor (AR). Ongoing research uses chemotherapy earlier in the disease course as well as explores the utility of combining cytotoxic chemotherapy with biologic agents.
authors.affiliation: Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, 525 East 68th Street, New York, NY, 10065, USA.
authors.forename: Elan
authors.initials: E
authors.lastname: Diamond
authors.forename: María del Carmen
authors.initials: Mdel C
authors.lastname: Garcias
authors.forename: Beerinder
authors.initials: B
authors.lastname: Karir
authors.forename: Scott T
authors.initials: ST
authors.lastname: Tagawa
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011241:Prednisone / Q000008:administration & dosage*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D011944:Receptors, Androgen / Q000097:blood; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome; D014481:United States
chemical_list: C410798:AR protein, human; D018931:Antineoplastic Agents, Hormonal; D011944:Receptors, Androgen; D043823:Taxoids; D011241:Prednisone